DBP receives EU funding SME instrument Phase I
"I am glad that we continue receiving support from the European Commission for our projects," comments CEO Igor Lokot. - It is tough competition for Horizon2020 funds in general and for the SME Instrument program In particular, and we see the positive decision as an important quality stamp for our actions and our ambitions".
More about SMEi phase I: https://ec.europa.eu/programmes/horizon2020/en/h2020-section/sme-instrument
More about SI-053: SI-053 is an innovative drug that is being developed by DBP for the treatment of operable brain cancers, in particular the most aggressive type glioblastoma. SI-053 is today at the edge of entering of the clinical phase of its development and the pre-clinical phase is expected to be completed within a few months. SI-053 has Orphan Drug Designation from EMA since 2016 and the international patent application to protect the technology has resulted so far in an approved patent for SI-053 in Eurasia.
This information is information that Double Bond Pharmaceutical International AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 8 of April 2019.